Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Phase 3

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

NCT07660796 · tracked via the Priya Life Science South Korea tracker
Phase
Phase 3
Started
2026-07-06
Last updated
2026-06-30

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

HCP1803-3HCP1803-4RLD2001-1RLD2001-2

HCP1803-3: Test drug

HCP1803-4: Test drug

RLD2001-1: Control drug

RLD2001-2: Control drug

Study summary

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions * mean sitSBP \< 180 mmHg and mean sitDBP \< 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1 * 140 mmHg ≤ mean sitSBP \< 180 mmHg and 60 mmHg ≤ mean sitDBP \< 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1 2. Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP \< 180 mmHg and 60 mmHg ≤ mean sitDBP \< 110 mmHg at Visit 2 Exclusion Criteria: 1. Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1 2. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1 3. Orthostatic hypotension with symptoms within 3 months prior to visit 1 4. Secondary hypertensive patient or suspected to be 5. Clinically significant hematological finding 6. Severe heart disease or severe neurovascular disease 7. Moderate or malignant retinopathy 8. Uncontrolled diabetes mellitus or type I diabetes mellitus 9. Active gout or hyperuricemia 10. Severe renal diseases 11. Severe or active hepatopathy 12. Hypokalemia or Hyperkalemia 13. Hyponatremia or Hypernatremia 14. Hypercalcemia 15. History of malignancy tumor 16. History of autoimmune disease 17. History of alcohol or drug abuse 18. Positive to pregnancy test, nursing mother, intention on pregnancy 19. Considered by investigator as not appropriate to participate in the clinical study with other reason

Primary outcome measure(s)

  • Change from baseline in sitting systolic blood pressure — Baseline, 10 weeks

Trial sites (1)

FacilityCityRegionStatus
Donggguk University Ilsan Hospital Goyang-si Gyeonggi-do
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07660796 on ClinicalTrials.gov ↗ ← All trials in South Korea